Development and validation of a pharmacy-based comorbidity measure in a population-based automated health care database

Pharmacotherapy

Volumn 33, Issue 2, 2013, Pages 126-136

  Dong, Yaa Hui ^a,b   Chang, Chia Hsuin ^a,c   Shau, Wen Yi ^d   Kuo, Raymond N ^a   Lai, Mei Shu ^a   Chan, K Arnold ^a,e  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b CATHAY GENERAL HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d Center for Drug Evaluation   (Taiwan)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Charlson index; Chronic disease score (CDS); Comorbidity measures; Health insurance claims database; Health services research; Pharmacoepidemiology

Indexed keywords

ADULT; AGED; ARTICLE; AUTOMATION; CALIBRATION; CHARLSON COMORBIDITY INDEX; CLASSIFICATION; CLINICAL INDICATOR; COHORT ANALYSIS; COMORBIDITY; DATA BASE; FEMALE; HEALTH CARE; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACY; PHARMACY BASED DISEASE INDICATOR; RETROSPECTIVE STUDY; SCORING SYSTEM; TAIWAN; VALIDATION PROCESS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; COMORBIDITY; DATABASES, FACTUAL; DELIVERY OF HEALTH CARE; FEMALE; HOSPITALIZATION; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; PHARMACY; POPULATION SURVEILLANCE; PROGRAM DEVELOPMENT; RETROSPECTIVE STUDIES; TAIWAN; YOUNG ADULT;

EID: 84875419035     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1176     Document Type: Article

References (59)

1. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987;40: 373-83.
2. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9CM administrative databases. J Clin Epidemiol 1992;45:613-9.
3. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9.
4. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9CM administrative data: differing perspectives. J Clin Epidemiol 1993;46:1075-9.
5. D'Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the Charlson comorbidity index with administrative data bases. J Clin Epidemiol 1996;49:1429-33.
6. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 2005;58:323-37.
7. Wilchesky M, Tamblyn RM, Huang A. Validation of diagnostic codes within medical services claims. J Clin Epidemiol 2004;57:131-41.
8. Lanes SF, Luise C. Bias due to false-positive diagnoses in an automated health insurance claims database. Drug Saf 2006;29:1069-75.
9. Rawson NSB, Shatin D. Assessing the validity of diagnostic data in large administrative healthcare utilization databases. In: Hartzema AG, Tilson HH, Chan KA, eds. Pharmacoepidemiology and therapeutic risk management. Cincinnati, OH: Harvey Whitney Books Company, 2008: 495-519.
10. Lorence DP, Ibrahim IA. Disparity in coding concordance: do physicians and coders agree? J Health Care Finance 2003;29:43-53.
11. Pongpirul K, Walker DG, Winch PJ, Robinson C. A qualitative study of DRG coding practice in hospitals under the Thai Universal Coverage scheme. BMC Health Serv Res 2011;11:71.
12. Lindenauer PK, Lagu T, Shieh MS, Pekow PS, Rothberg MB. Association of diagnostic coding with trends in hospitalizations and mortality of patients with pneumonia, 2003-2009. JAMA 2012;307:1405-13.
13. Levy AR, O'Brien BJ, Sellors C, Grootendorst P, Willison D. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol 2003;10:67-71.
14. McKenzie DA, Semradek J, McFarland BH, Mullooly JP, McCamant LE. The validity of Medicaid pharmacy claims for estimating drug use among elderly nursing home residents: the Oregon experience. J Clin Epidemiol 2000;53:1248-57.
15. von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992;45:197-203.
16. Johnson RE, Hornbrook MC, Nichols GA. Replicating the Chronic Disease Score (CDS) from automated pharmacy data. J Clin Epidemiol 1994;47:1191-9.
17. Malone DC, Billups SJ, Valuck RJ, Carter BL. Development of a chronic disease indicator score using a Veterans Affairs Medical Center medication database. IMPROVE Investigators. J Clin Epidemiol 1999;52:551-7.
18. Lamers LM. Pharmacy costs groups: a risk-adjuster for capitation payments based on the use of prescribed drugs. Med Care 1999;37:824-30.
19. Clark DO, Von Korff M, Saunders K, Baluch WM, Simon GE. A chronic disease score with empirically derived weights. Med Care 1995;33:783-95.
20. Putnam KG, Buist DSM, Fishman P, et al. Chronic disease score as a predictor of hospitalization. Epidemiology 2002;13:340-6.
21. Fishman PA, Goodman MJ, Hornbrook MC, Meenan RT, Bachman DJ, .O'Keeffe Rosetti MC. Risk adjustment using automated ambulatory pharmacy data: the RxRisk model. Med Care 2003;41:84-99.
22. Sales AE, Liu CF, Sloan KL, et al. Predicting costs of care using a pharmacy-based measure risk adjustment in a veteran population. Med Care 2003;41:753-60.
23. Johnson ML, El-Serag HB, Tran TT, Hartman C, Richardson P, Abraham NS. Adapting the Rx-Risk-V for mortality prediction in outpatient populations. Med Care 2006;44:793-7.
24. Schneeweiss S, Wang PS, Avorn J, Glynn RJ. Improved comorbidity adjustment for predicting mortality in Medicare populations. Health Serv Res 2003;38:1103-20.
25. Schneeweiss S, Wang PS, Avorn J, Maclure M, Levin R, Glynn RJ. Consistency of performance ranking of comorbidity adjustment scores in Canadian and U.S. utilization data. J Gen Intern Med 2004;19:444-50.
26. Fan VS, Maciejewski ML, Liu CF, McDonell MB, Fihn SD. Comparison of risk adjustment measures based on self-report, administrative data, and pharmacy records to predict clinical outcomes. Health Serv Outcomes Res Method 2006;6:21-36.
27. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claim data. Am J Epidemiol 2001;154:854-64.
28. Lix LM, Quail J, Teare G, Acan B. Performance of comorbidity measures for predicting outcomes in population-based osteoporosis cohorts. Osteoporos Int 2011;22:2633-43.
29. Quail JM, Lix LM, Osman BA, Teare GF. Comparing comorbidity measures for predicting mortality and hospitalization in three population-based cohorts. BMC Health Serv Res 2011;11:146.
30. Bari MD, Virgillo A, Matteuzzi D, et al. Predictive validity of measures of comorbidity in older community dwellers: the Insufficienza Cardiaca negli Anziani Residenti a Dicomano Study. J Am Geriatr Soc 2006;54:210-6.
31. Zekry D, Valle BH, Michel JP, et al. Prospective comparison of six co-morbidity indices as predictors of 5 years post hospital discharge survival in the elderly. Rejuvenation Res 2010;13:675-82.
32. National Health Insurance Research Database. Available from http://w3.nhri.org.tw/nhird/en/Background.html. Accessed April 18, 2011.
33. Chu YT, Ng YY, Wu SC. Comparison of different comorbidity measures for use with administrative data in predicting short- and long-term mortality. BMC Health Serv Res 2010;10:140.
34. Kuo RN, Dong YH, Liu JP, Chang CH, Shau WY, Lai MS. Predicting healthcare utilization using a pharmacy-based metric with the WHO's Anatomic Therapeutic Chemical algorithm. Med Care 2011;49:1031-9.
35. Chen CH, Yang PM, Hung GT, Lee HS, Sung JL, Sheu JC. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc 2007;106:148-55.
36. Dienstag JL, Hepatitis B. Virus Infection. N Engl J Med 2008;359:1486-500.
37. Wu HB, Lee MC, Lai KH, et al. Physicians' knowledge about pharmacological management of cancer pain-with special reference on their prescribing responses to simulated patients with cancer pain. Acta Anaesthesiol Taiwan 2006;44:61-71.
38. National Health Insurance Act. Available from http://www.nhi.gov.tw/ webdata/webdata.aspx?menu=17&menu-id=660&WD-ID=674&webdata-id=1865. Accessed April 18, 2011.
39. Longitudinal Health Insurance Database. Available from http://w3.nhri.org.tw/nhird/en/Data-Subsets.html#S3. Accessed April 18, 2011.
40. World Health Organization Collaborating Centre for Drug Statistics Methodology. Available from http://www.whocc.no/atcddd/. Accessed April 18, 2011.
41. Anonymous. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004;44:20-9.
42. Milavetz G. Cystic fibrosis. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach, 7th ed. New York, NY: McGraw- Hill Companies, 2008: 535-46.
43. Micromedex Healthcare Series. Available from http://www.thomsonhc.com. Accessed April 18, 2011.
44. The license of neostigmine, issued by the Department of Health, Taiwan. Available from http://licnquery.fda.gov.tw/DO8180A.asp. Accessed April 18, 2011. [in Chinese].
45. AHFS Pharmacologic-Therapeutic Classification System. Available from http://www.ahfsdruginformation.com/class/index.aspx. Accessed April 18, 2011.
46. Steyerberg EW. Clinical prediction models: a practical approach to development, validation, and updating. New York, NY: Spring Science+Business Media, LLC., 2009.
47. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007;115:928-35.
48. Cook NR, Ridker PM. Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. Ann Intern Med 2009;150:795-802.
49. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;30:157-72.
50. Klungel OH, Martens EP, Psaty BM, et al. Methods to assess intended effects of drug treatment in observational studies are reviewed. J Clin Epidemiol 2004;57:1223-31.
51. Chan KA, Andrade SE, Boles M, et al. Inhibitors of hydroxymethylglutaryl- coenzyme A reductase and risk of fracture among older women. Lancet 2000;355:2185-8.
52. National Drug Code Directory. Available from http://www.accessdata.fda. gov/scripts/cder/ndc/default.cfm. Accessed April 18, 2011.
53. van Walraven C, Austin PC, Jennings A, Quan H, Forster AJ. A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data. Med Care 2009;47:626-33.
54. Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol 2011;64:749-59.
55. Lemke KW, Weiner JP, Clark JM. Development and validation of a model for predicting inpatient hospitalization. Med Care 2012;50:131-9.
56. Bernstein RH. New arrows in the quiver for targeting care management: high-risk versus high-opportunity case identification. J Ambul Care Manage 2007;30:39-51.
57. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996;49:1373-9.
58. Arbogast PG, Ray WA. Use of disease risk scores in pharmacoepidemiologic studies. Stat Methods Med Res 2009;18:67- 80.
59. Waters E, Davis E, Nicolas C, Wake M, Lo SK. The impact of childhood conditions and concurrent morbidities on child health and well-being. Child Care Health Dev 2008;34:418-29.